Three companies looking for investors to support their launch in 2021.

A seed stage safety syringe manufacturer based in Kenya due to launch in Q4 2021. We will become one of the worlds largest producers of safety syringes globally and will manufacture the new Minipen2 Insulin syringe for Medtech Concept AB.

A miniature insulin syringe manufacturer based in Sweden with no direct competition and a target addressable market of 300 million users. Manufacturing is scheduled to start in Q4-2021. Signed contracts with 2 distributors and €30m in pipeline sales. Up to €2 million in equity and loans required to fund growth.

Medtrac have three products in development :

Digital Pathogen Sensor (DPS). A contactless non-invasive test that removes the need for DNA collection and consumables to perform a rapid & reliable test in seconds. No chemicals, swabs, syringes, vials or primers are used. Currently at Proof of concept testing stage. Patent application in progress. Scientific validation to start once the patent is accepted.

Rapid Scan – Our Public Transportation implementation of the Digital Pathogen Sensor (DPS) to detect COVID-19 and variants.

Rapid Test – Our flagship product offers an unparalleled level of detail about your health using your mobile phone to capture data which is analysed by AI with results from our digital lab that uses dry blood analysis. An early working version is undergoing live trials in a European Private Hospital and further development of the platform is planned subject to seed funding.